Table 5: Multivariate survival analysis of PFS and OS in 70 patients with endometrial carcinoma.

HR95% CI -value

Progression-free survival
 FIGO stage5.5710.983–31.5670.052
 Grade2.4930.213–29.1710.467
 Lymph node metastasis0.7000.190–2.5780.592
 Depth of myometrial invasion1.7660.286–10.9020.540
 LVS involvement3.9830.463–34.2490.208
 Peritoneal cytology8.4971.664–43.3760.010
 Wnt7a expression0.1930.019–1.9550.164
Overall survival
 FIGO stage1.7340.469–6.4070.409
 Grade0.8390.080–8.8440.884
 Lymph node metastasis0.8460.238–3.0060.797
 LVS involvement7.6830.867–68.0430.067
 Peritoneal cytology5.0821.258–20.5250.022
 Wnt7a expression0.7370.116–4.6960.747

FIGO: International Federation of Gynecology and Obstertics; LVS: lymph vascular space; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval and *Cox regression test.